The stock of Mustang Bio Inc (MBIO) has gone down by -5.16% for the week, with a 7.01% rise in the past month and a -36.29% drop in the past quarter. The volatility ratio for the week is 11.53%, and the volatility levels for the past 30 days are 14.14% for MBIO. The simple moving average for the last 20 days is -12.27% for MBIO’s stock, with a simple moving average of -53.89% for the last 200 days.
Is It Worth Investing in Mustang Bio Inc (NASDAQ: MBIO) Right Now?
MBIO has 36-month beta value of 1.86. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MBIO is 33.65M, and currently, short sellers hold a 1.59% ratio of that float. The average trading volume of MBIO on November 14, 2024 was 1.90M shares.
MBIO) stock’s latest price update
The stock price of Mustang Bio Inc (NASDAQ: MBIO) has dropped by -3.21 compared to previous close of 0.24. Despite this, the company has seen a fall of -5.16% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price requirement through January 31, 2025 and the $2.5 million stockholders’ equity requirement through February 18, 2025. The Company is considering all available options that may enable it to timely evidence compliance with the continued listing criteria and maintain its listing on Nasdaq; however, there can be no assurance that the Company will be able to do so.
Analysts’ Opinion of MBIO
Many brokerage firms have already submitted their reports for MBIO stocks, with BTIG Research repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to BTIG Research is $11 based on the research report published on May 18, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $9. The rating they have provided for MBIO stocks is “Buy” according to the report published on October 02nd, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to MBIO, setting the target price at $7 in the report published on November 20th of the previous year.
MBIO Trading at -5.47% from the 50-Day Moving Average
After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.40% of loss for the given period.
Volatility was left at 14.14%, however, over the last 30 days, the volatility rate increased by 11.53%, as shares surge +8.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.60% lower at present.
During the last 5 trading sessions, MBIO fell by -4.60%, which changed the moving average for the period of 200-days by -83.57% in comparison to the 20-day moving average, which settled at $0.2680. In addition, Mustang Bio Inc saw -82.58% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBIO
Current profitability levels for the company are sitting at:
- -8.36 for the present operating margin
- 0.53 for the gross margin
The net margin for Mustang Bio Inc stands at -8.12. The total capital return value is set at 3.07. Equity return is now at value -1191.31, with -168.70 for asset returns.
Based on Mustang Bio Inc (MBIO), the company’s capital structure generated -0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -16.95. The debt to equity ratio resting at -0.11. The interest coverage ratio of the stock is 8.62.
Currently, EBITDA for the company is -48.06 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 2.06. The receivables turnover for the company is 12.16for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
To put it simply, Mustang Bio Inc (MBIO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
